# FOURLIGHT-3 (NCT06760637)

> Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06760637
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Breast Cancer
- Interventions: PF-07220060; letrozole; abemaciclib; palbociclib; ribociclib
- Enrollment: 1035
- Primary outcome: Progression Free Survival (PFS) by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6
- X videos: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fourlight-3-nct06760637